Navigation Links
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Date:11/17/2010

ent over the current best standard of care available in the USA. We are now well positioned to advance RVX-208 to the next clinical trial having witnessed the substantial and consistent elevation of HDL by ApoA-I production; which strongly indicates that RVX-208 should remove unwanted plaque from the arterial wall which is our main goal."

Resverlogix Senior Vice President of Medical Affairs Dr. Jan Johansson stated, "In patients who received the newer class of statins and had baseline HDL below 45mg/dL, an important high-risk subpopulation, the middle dose of 200 mg saw the most pronounced increases of 12% in ApoA-I (p<0.002), 21% in HDL cholesterol (p<0.015) and 32% in large particle HDL (p<0.018). We are delighted by these results and now have a much better understanding of what doses to use and what patient population to target moving forward in our ASSURE Phase 2b trial." 

An additional presentation at the AHA meeting was given by Dr. Norman Wong, Chief Scientific Officer of Resverlogix, containing new data detailing the effects of RVX-208 in vivo. The presentation was titled "RVX-208: An Orally Administrated Small Molecule Reduces Atherosclerosis in ApoE Null Mouse and Raises ApoA-I/HDL in Humans". In the ApoE null mice model of atherosclerosis, the oral administration of RVX-208 reduced aortic plaques in two separate models.  The presented model showed plaque reductions of up to 41%. Resverlogix to Host Webcast on ASSERT Phase 2 Trial Results - change in time
Resverlogix Corp. will host a live teleconference and webcast today at 2:15 pm Central/1:15 pm Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 2 clinical trial (ASSERT) for RVX-208. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following addre
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
2. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
3. Resverlogixs Phase 2 ASSURE Trial Amended
4. Resverlogix Scientific Data Presented at EAS Congress
5. Resverlogix Completes Dosing for ASSERT Trial
6. Resverlogix Notice of Conference Call & Webcast for Year End Update
7. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
8. Resverlogix Completes Patient Recruitment for ASSERT Trial
9. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
10. Resverlogix Presenting at Biotech Showcase
11. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- The new , Healthcare and Life Sciences ... on PharmaBoardroom.com for free download , looks ... Spanish economy in 2009, and the austerity measures that followed, ... in times of trouble. "Despite the crisis, ... market, and the general conditions to invest are favorable to ...
(Date:9/18/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Sodium ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... China Acetic Acid Industry" is a professional and ... and Global Acetic Acid Market. The report ...
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... May 27, 2009 Senomyx, Inc. (Nasdaq: ... technologies to discover and develop novel flavor ingredients for ... the appointment of David L. Linemeyer, Ph.D., to the ... 20 years of experience in directing biology research programs ...
... May 27 The atherosclerosis vaccine,development program by ... EUROTRANS-BIO call. The respective project is being carried ... The aim of,atherosclerosis vaccination is to increase the ... the blood and thus reduce the occurrence of,harmful ...
... Oncothyreon Inc. (Nasdaq: ONTY ) (TSX: ONY) announced ... shares of its common stock and warrants to purchase 2,909,244 ... $11.1 million on May 26, 2009. Oncothyreon sold the shares ... one share and a warrant to purchase 0.75 shares of ...
Cached Biology Technology:SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 2SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 3AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3Oncothyreon announces closing of $11.1 million registered direct financing 2
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
(Date:9/18/2014)... Sydney, September 18, 2014 Elsevier, a world-leading ... and services, and the Australasian Research Management Society ... young scientists at the 5th Scopus Young Researcher ... held earlier today at the National Convention Centre ... conference, was attended by guests representing Australia,s and ...
(Date:9/18/2014)... lives nestling in the protective tentacles of host anemones, ... travel hundreds of kilometres across the open ocean. Although ... been predicted, this is the first time that the ... been observed. , Dr Steve Simpson, Senior Lecturer in ... Exeter, and colleagues from the Australian Research Council Centre ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... of 14 satellites currently in orbit and the National ... have been able to observe the Earths environment to ... world. The use of remote sensing technology aids ... most common and deadly infectious diseases today such as ...
... . , Fall, the season of colors: Leaves ... green and the simultaneous appearance of these other colors are ... Krutler at the University of Innsbruck (Austria) has now determined ... produces the same decomposition products as those in brightly colored ...
... Campus in Sydney have developed a novel way to control ... often speeds death. The findings, published in Nature ... condition, giving people the strength to survive treatment and improve ... the Centre for Immunology at St Vincents Hospital and the ...
Cached Biology News:NASA technology helps predict and prevent future pandemic outbreaks 2Ripe fruit preferred 2Australian researchers develop treatment to treat obesity 2
... your protein is in solution or in a ... mass spectrometry. Proteins will be digested to produce ... of the peptides are determined by MALDI-TOF, and ... peaks (peptides) from MALDI-TOF will be determined by ...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
Request Info...
Biology Products: